EV71 clinical trials
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses EV71 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 1
Sinovac Biotech Co., Ltd (2) · Enimmune Corporation (2) · China National Biotec Group Company Limited (1) · Medigen Vaccine Biologics Corp. (1) · Shandong Province Centers for Disease Control and Prevention (1)
Often tested with
Tested in the same studies.
Influenza Vaccines (1) · Aluminum phosphate (1)
Studies
Open first, then newest update. How each study uses EV71 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).CompletedPhase 1/2Sinovac Biotech Co., LtdNCT06754384Written as EV71 inactivated enterovirus vaccine (Vero cell) )(for ages 6-71 months）
- Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza VaccineCompletedPhase 4China National Biotec Group Company LimitedNCT04091880Written as EV71 vaccine and influenza vaccine
- A Study to Evaluate the Immunogenicity and Safety of EV71 Vaccine in Pediatric SubjectsCompletedPhase 2Enimmune CorporationNCT03268083Written as EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AI(OH)3] per dose)
- Immunogenicity and Safety of Two Different Commercial EV71 VaccinesCompletedPhase 4Sinovac Biotech Co., LtdNCT03873740Written as EV71 inactived vaccine（Vero cells）
- Clinical Study on Combined Immune Effect of EV71 Inactivated VaccineStatus unknownPhase 4Shandong Province Centers for Disease Control and PreventionNCT03519568Written as EV71 (inoculation vaccine)
- A Clinical Study for Inactivated Vaccine Against EV71CompletedPhase 2Medigen Vaccine Biologics Corp.NCT02200237Written as EV71 with adjuvant aluminium phosphate
- A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months OldCompletedPhase 2Enimmune CorporationNCT02777411Written as EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)
As the comparator · 3 — what is tested is compared with EV71
- The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza VaccineCompletedPhase 4Zhejiang Provincial Center for Disease Control and PreventionNCT04133584Written as EV71
- Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization VaccinesCompletedPhase 4Sinovac Biotech Co., LtdNCT04111432Written as EV71 Vaccine only
- Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With EPI VaccinesCompletedPhase 4Sinovac Biotech Co., LtdNCT03274102Written as EV71 Vaccine only